Compare PAGP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAGP | PTCT |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | 991 |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.0B |
| IPO Year | 2013 | 2006 |
| Metric | PAGP | PTCT |
|---|---|---|
| Price | $27.85 | $69.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 17 |
| Target Price | $22.11 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 1.5M | 755.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | ★ 370.00 | 264.48 |
| EPS | 0.27 | ★ 0.90 |
| Revenue | ★ $44,262,000,000.00 | $264,734,000.00 |
| Revenue This Year | $10.57 | N/A |
| Revenue Next Year | N/A | $17.70 |
| P/E Ratio | $103.33 | ★ $79.19 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $16.69 | $57.74 |
| 52 Week High | $28.70 | $90.87 |
| Indicator | PAGP | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 45.92 |
| Support Level | $22.78 | $67.57 |
| Resistance Level | N/A | $73.86 |
| Average True Range (ATR) | 0.51 | 2.00 |
| MACD | 0.12 | 0.17 |
| Stochastic Oscillator | 73.47 | 54.08 |
Plains GP Holdings LP owns and operates midstream energy infrastructure and provides logistics services for crude oil, natural gas liquids (NGL), and natural gas. The group manages its operations through two operating segments: Crude Oil segment operations generally consist of gathering and transporting crude oil using pipelines (including gathering systems), trucks, and, at times, on barges or railcars; and NGL segment operations involve NGL storage and terminalling from NGL assets located in the Southwestern United States. It generates the majority of its revenue from the Crude Oil segment. Its geographic markets are the United States and Canada. It generates the majority of its revenue from the United States.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.